Literature DB >> 17673902

Genome scan implicates adhesion biological pathways in secondary leukemia.

C Hartford1, W Yang, C Cheng, Y Fan, W Liu, L Treviño, S Pounds, G Neale, S C Raimondi, A Bogni, M E Dolan, C-H Pui, M V Relling.   

Abstract

The genetic risk factors for etoposide-induced leukemia with MLL translocations remain largely unknown. To identify genetic risk factors for and novel characteristics of secondary leukemia, we profiled 116,204 single nucleotide polymorphisms (SNPs) in germline and paired leukemic cell DNA from 13 secondary leukemia/myelodysplasia cases and germline DNA from 13 matched and 156 unmatched controls, all with acute lymphoblastic leukemia treated with etoposide. We analyzed global gene expression from a partially overlapping cohort. No single locus was altered in most cases. We discovered 81 regions of loss of heterozygosity (LOH) in leukemic blasts and 309 SNPs whose allele frequencies differed in cases vs controls. Candidate genes were prioritized on the basis of genes whose SNPs or expression differentiated cases from controls or showed LOH or copy number change in germline vs paired blast DNA from the 13 cases. Three biological pathways were altered: adhesion, Wnt signaling and regulation of actin. Validation experiments using a genome scan for etoposide-induced leukemogenic MLL chimeric fusions in 15 HapMap cell lines also implicated genes involved in adhesion, a process linked to de novo leukemogenesis. Independent clinical epidemiologic and in vitro genome-wide approaches converged to identify novel pathways that may contribute to therapy-induced leukemia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17673902     DOI: 10.1038/sj.leu.2404885

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  14 in total

Review 1.  Genome-wide association studies in pharmacogenomics.

Authors:  Ann K Daly
Journal:  Nat Rev Genet       Date:  2010-04       Impact factor: 53.242

Review 2.  Pharmacogenomic discovery using cell-based models.

Authors:  Marleen Welsh; Lara Mangravite; Marisa Wong Medina; Kelan Tantisira; Wei Zhang; R Stephanie Huang; Howard McLeod; M Eileen Dolan
Journal:  Pharmacol Rev       Date:  2009-12       Impact factor: 25.468

Review 3.  Clinical association between pharmacogenomics and adverse drug reactions.

Authors:  Zhi-Wei Zhou; Xiao-Wu Chen; Kevin B Sneed; Yin-Xue Yang; Xueji Zhang; Zhi-Xu He; Kevin Chow; Tianxin Yang; Wei Duan; Shu-Feng Zhou
Journal:  Drugs       Date:  2015-04       Impact factor: 9.546

Review 4.  Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?

Authors:  Heinrike Schmeling; Gerd Horneff; Susanne M Benseler; Marvin J Fritzler
Journal:  Nat Rev Rheumatol       Date:  2014-08-12       Impact factor: 20.543

Review 5.  Acute leukemia as a secondary malignancy in children and adolescents: current findings and issues.

Authors:  Nobuko Hijiya; Kirsten K Ness; Raul C Ribeiro; Melissa M Hudson
Journal:  Cancer       Date:  2009-01-01       Impact factor: 6.860

Review 6.  Use of cell lines in the investigation of pharmacogenetic loci.

Authors:  Wei Zhang; M Eileen Dolan
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

7.  Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.

Authors:  Kjeld Schmiegelow; Ibrahim Al-Modhwahi; Mette Klarskov Andersen; Mikael Behrendtz; Erik Forestier; Henrik Hasle; Mats Heyman; Jon Kristinsson; Jacob Nersting; Randi Nygaard; Anne Louise Svendsen; Kim Vettenranta; Richard Weinshilboum
Journal:  Blood       Date:  2009-02-17       Impact factor: 22.113

Review 8.  Pharmacogenetics in acute lymphoblastic leukemia.

Authors:  Meyling H Cheok; Nicolas Pottier; Leo Kager; William E Evans
Journal:  Semin Hematol       Date:  2009-01       Impact factor: 3.851

9.  Pharmacogenomic genome-wide association studies: lessons learned thus far.

Authors:  James J Crowley; Patrick F Sullivan; Howard L McLeod
Journal:  Pharmacogenomics       Date:  2009-02       Impact factor: 2.533

Review 10.  Etoposide sensitivity does not predict MLL rearrangements or risk of therapy-related acute myeloid leukemia.

Authors:  J Yang; A Bogni; C Cheng; W K Bleibel; X Cai; Y Fan; W Yang; J C C Rocha; D Pei; W Liu; M E Dolan; C-H Pui; M V Relling
Journal:  Clin Pharmacol Ther       Date:  2008-05-28       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.